Company intelligence / Profile preview
InterK Peptide Therapeutics
Sydney, New South Wales, Australiainterk.com.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead peptides have demonstrated proof-of-concept results with inhibition of cancer growth in animal models, immune system modulation (Th1 response, selective Lck activation), and have shown immunomodulatory effects in human and mouse immune cells; partnerships with academic and CRO collaborators have strengthened IP and investment prospects
- Therapeutic areas
- ImmunologyInfectious DiseasesDermatologyOncologyNeurology
- Modalities
- PeptidesSynthetic peptidesPeptide-drug conjugate
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Concept Life SciencesMalvern Panalytical
Beyond the preview
Go deeper on InterK Peptide Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InterK Peptide Therapeutics.